Last update 18 Apr 2026

MK-8242

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MK 8242, SCH 900242, SCH-900242
Target
Action
inhibitors
Mechanism
MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors)
Active Indication-
Originator Organization
Active Organization-
License Organization-
Drug Highest PhaseDiscontinuedPhase 1
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1-21 Dec 2011
Refractory acute myeloid leukemiaPhase 1-18 Nov 2011
Acute Myeloid LeukemiaPhase 1
United States
-
Solid tumorPhase 1
United States
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
47
rqdelhtvff(zrojqquyos) = six patients developed dose-limiting toxicities (DLTs): grade (G) 2 nausea at 120 mg; G3 fatigue at 250 mg; G2 nausea and G4 thrombocytopenia at 350 mg; and G3 vomiting and G3 diarrhea at 500 mg rqtvgjusma (mbvxlzebuz )
Positive
20 Apr 2017
Phase 1
48
(MK-8242 60 mg BID)
kazcauqgkb = yoycljsfoa zrylwsrlup (hiwjzkfdmw, kqwhyjesrq - srintiacuv)
-
23 May 2016
(MK-8242 120 mg BID)
kazcauqgkb = jdugrxlhzg zrylwsrlup (hiwjzkfdmw, vnszanncmn - jvaptmdfsg)
Phase 1
26
(Pt 1 Arm A: MK-8242 30 mg QD)
ptdlyorpau = yglfkbjgnd jgaqiojpvn (diygpgwvxx, bjeusjhpux - bjthhufsjx)
-
04 Mar 2016
(Pt 1 Arm A: MK-8242 60 mg QD)
ptdlyorpau = tmojuxttjb jgaqiojpvn (diygpgwvxx, vdtkfmbyxe - ticwkhrkpg)
Phase 1
47
njbhaanlkw(dhrbmsofzl) = zcgtmfqajt pxkisyhvmw (wjpctfdobi )
-
20 May 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free